Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide is not recommended during pregnancy. That is the clear position of the UK medicines regulator and the manufacturers: women who are pregnant, breastfeeding, or actively trying to conceive should not use semaglutide in any form, including Wegovy. If you discover you are pregnant while on treatment, stop taking it and speak to your GP or midwife the same day. Semaglutide is a prescription-only medicine; a prescriber decides suitability in every individual case, and pregnancy changes that picture entirely.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The short answer is no. Both the Wegovy SmPC (the prescribing summary held on the electronic Medicines Compendium) and the NHS medicines page for semaglutide are unambiguous: use during pregnancy is not recommended. This is not a precaution that varies by trimester or dose, it applies across the full pregnancy.
The reason is partly the absence of adequate human safety data, and partly what animal studies found. In reproductive toxicology studies, semaglutide caused foetal abnormalities and growth restriction at exposures similar to the doses used in people. That is not proof of harm in humans, but it is enough for regulators to say the risk cannot be justified. Weight management, while genuinely important for long-term health, is not a clinical priority that outweighs those concerns during pregnancy.
If you discover you are pregnant while a Wegovy pen is sitting in your fridge door or a tablet is part of your morning routine, stop the medicine and contact your GP or midwife the same day. They can review your antenatal care plan and, if needed, flag the exposure to the appropriate monitoring service. Do not wait for your next scheduled review.
This question comes up frequently, and the guidance is similarly cautious. NHS England's guidance on weight-management injections advises that women who are planning a pregnancy should discuss stopping semaglutide with their prescriber before trying to conceive, allowing time for the medicine to clear the body.
Semaglutide has a long half-life, it stays in the body for several weeks after the last dose. A wash-out period is therefore sensible before conception is attempted. The exact length of that window depends on the form of semaglutide (injection versus tablet), the dose reached, and individual factors your prescriber will know. That conversation belongs with your GP, a specialist, or the prescriber who manages your treatment, not a one-size figure on a webpage.
One additional consideration: semaglutide can affect the absorption of oral contraceptives, which means additional contraceptive precautions may be relevant while on treatment. The relationship between Wegovy and pregnancy planning involves more moving parts than many people expect, so early conversations with a clinician matter.
Semaglutide passes into breast milk in animal studies. On that basis, breastfeeding while taking semaglutide is not recommended either. Once breastfeeding has ended and a reasonable recovery period has passed, restarting weight management treatment may be an option, but only with a fresh clinical assessment.
Weight often changes substantially during pregnancy and the postnatal period. A prescriber will want to reassess BMI, any weight-related conditions, and your overall health picture before recommending treatment. That is a different clinical conversation from the one that led to the original prescription, and it deserves proper time. Our page on taking Wegovy when pregnant covers the postnatal restart question in more detail.
If you had been taking semaglutide before conceiving and want to understand your options postnatally, our team is available seven days a week. You can also learn about the clinical oversight behind our service to understand how these conversations are handled.
Pregnancy intersects with semaglutide treatment in three distinct situations: an unplanned pregnancy during treatment, a planned pregnancy where you want to stop safely, and a return to treatment postnatally. Each needs a different conversation, and none of them should be managed by self-adjusting your dose or relying on general online information.
Your first contact should always be your GP or midwife if you are already pregnant, and if you want a thorough answer to the question of whether you can take Wegovy when pregnant, our dedicated page works through the evidence and guidance in detail. For planned pregnancy or postnatal restarting, your prescriber (including a prescriber at a regulated service like ours) can advise on timing and next steps, and our dedicated page on taking semaglutide while pregnant sets out the key considerations in full. If you have wider questions about how Wegovy works and what treatment involves, that context may help frame those conversations with your clinical team.
The MHRA's Yellow Card scheme allows anyone to report unexpected effects, including anything noticed during pregnancy, you can do so at yellowcard.mhra.gov.uk. If you are thinking about weight management treatment outside pregnancy and want to understand your options, start a free consultation and a GPhC-registered prescriber will review your details the same day. Patients based in Merseyside can also visit our Wegovy Liverpool service page for information on accessing treatment locally.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.